Theriva Biologics (TOVX)

• Market cap: $7.31M
• 1 day: -3.58%
• 5 days: -7.98%
• 1 month: -22.88%
• 3 months: -29.99%
• 6 months: -76.86%
• Year to date: -81.07%
• 1 year: -78.6%
• 5 years: -99.58%
• 10 years: -100%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Employees: 22